Iovance Biotherapeutics is betting that the right biomarker filter can rescue a TIL therapy program in lung cancer where unselected patients haven’t responded well enough. The October 29 filing discloses updated results from Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial in previously treated non-squamous metastatic non-small cell lung cancer, alongside a new biomarker-enriched patient selection approach the company is calling a precision TIL strategy for lifileucel. The simultaneous announcement of updated data and a redesigned selection strategy is a signal that the unselected population produced results the company doesn’t want to defend as a registration path.
Lifileucel (Amtagvi) earned FDA approval in February 2024 for unresectable or metastatic melanoma after prior PD-1 therapy, making it the first approved TIL cell therapy in oncology. Extending it into NSCLC is a logical commercial ambition, but lung cancer is a harder environment: patients arrive with more heterogeneous tumor biology, prior checkpoint inhibitor exposure is nearly universal in the metastatic setting, and manufacturing a viable TIL product from lung tumors is operationally more demanding than from melanoma lesions. Cohort 1 and Cohort 2 of IOV-LUN-202 represent the program’s attempt to establish whether lifileucel can generate a clinically meaningful signal before committing to a pivotal design.
The pivot to a biomarker-enriched strategy is where the real trial design question sits. Enrichment approaches can sharpen response rates on paper by excluding patients least likely to respond, which makes a Phase 2 readout look better but narrows the eventual label and the addressable patient pool. Iovance will need to show that the selected biomarker is analytically validated, reproducible across manufacturing sites, and prospectively predictive rather than retrospectively convenient. The 8-K body itself does not detail the specific biomarker or the response data from the two cohorts; those figures are expected in the attached press release (Exhibit 99.1), which is incorporated by reference but not reproduced here.
What to watch now is whether the precision TIL strategy gets embedded in a protocol amendment that resets the primary endpoint population, or whether Iovance presents it as hypothesis-generating ahead of a separately powered cohort. That structural choice will determine how quickly IOV-LUN-202 can support a registration conversation with FDA.
Source link: https://www.sec.gov/Archives/edgar/data/1425205/000110465926120261/tm2628468d1_8k.htm
LUN-202: the facts in one place
- Also written: IOV-LUN-202, LN-145, lifileucel
- Sponsor: Iovance Biotherapeutics, Inc.
- Mechanism: Autologous tumor-infiltrating lymphocyte (TIL) cell therapy: TILs harvested from patient tumor, expanded ex vivo, and re-infused following lymphodepletion and interleukin-2 administration
- Indication studied: Metastatic non-small cell lung cancer (NSCLC) progressed after prior chemoimmunotherapy (platinum-based chemotherapy and anti-PD-1 therapy), without EGFR, ROS1, or ALK genomic mutations
- Phase: Phase 2
- Enrollment: Approximately 80 non-squamous NSCLC patients expected in final dataset (Cohorts 1 and 2); 69 patients in updated analysis
- Primary endpoint: Objective response rate (ORR) per RECIST v1.1
- Headline result: ORR of 24.6% in 69 patients (Cohorts 1 and 2, data cutoff October 14, 2026); biomarker-enriched subgroup (KRAS wild-type, HER2 wild-type, current or former smoking) ORR of 59.1%
- Registry identifier: NCT04614103
- Current status: Cohorts 1 and 2 completing enrollment; registrational cohort POSITILITY enrolling from November 2026; sBLA planned for 2027
- Clinical hold: December 2023
- Clinical hold lifted: March 2024
- Data cutoff (updated results): October 14, 2026
- Press release (updated results): October 29, 2026
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
